Post hoc analysis of the phase 3 Vivacity-MG3 trial in adults with generalised myasthenia gravis: nipocalimab added to standard care gave higher rates of sustained MG-ADL and QMG improvement over 24 weeks than placebo, including sustained composite response (OR 6.3).
Secondary analysis
Vu et al. Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study